ZYXI241220C2500
- 0.00
- 0.000.00%
Zynex Newsroom
Zynex UCSF Study Results Demonstrate Laser Technology Benefits in Resolving Racial Bias of Current LED Pulse Oximeters
Zynex Inc. Achieves $200M Milestone and Sets Ambitious Goals for 2025 | NASDAQ:ZYXI
ZYXI Stock Gains on the Completion of NiCO's Clinical Verification Trial
H.C. Wainwright Maintains Zynex(ZYXI.US) With Buy Rating, Maintains Target Price $17
Express News | HC Wainwright & Co. Reiterates Buy on Zynex, Maintains $17 Price Target
Analysts Are Bullish on These Healthcare Stocks: Zynex (ZYXI), KalVista Pharmaceuticals (KALV)
Zynex Eyes FDA Submission for NiCO Pulse Oximeter Following Successful Verification Trial | NASDAQ:ZYXI
Zynex Announces Completion of Its Laser Pulse Oximetry Trial
Zynex Announces Open Oximetry Project Membership
Biden Proposes Medicare, Medicaid Coverage of Obesity Drugs
Zynex Medical COO Discusses Expanding Role in Non-opioid Pain Management | NASDAQ:ZYXI
A Note On Zynex, Inc.'s (NASDAQ:ZYXI) ROE and Debt To Equity
Zynex's (NASDAQ:ZYXI) Soft Earnings Are Actually Better Than They Appear
Results: Zynex, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Earnings Call: Zynex Reports Steady Q3 Growth, Plans for Future Expansion
Q3 2024 Zynex Inc Earnings Call
RBC Capital Maintains Zynex(ZYXI.US) With Buy Rating, Maintains Target Price $11
Zynex Analyst Ratings
H.C. Wainwright Maintains Zynex(ZYXI.US) With Buy Rating, Raises Target Price to $17
Zynex's Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating